Life Extension Blood Test Super Sale

Life Extension Magazine

LE Magazine January 2004
image
Melatonin and Cancer Treatment
By Eileen M. Lynch, PhD Oncology Research Scientist

Reprint of a letter from Cancer Treatment Centers of America

November 6, 2003

Mr. William Faloon
Life Extension Foundation
3600 West Commercial Blvd.
Fort Lauderdale, FL 33309

Re: Status of Protocol CTCA 01-07: A Multi-Center Randomized, Double-Blind, Trial Evaluating the Chronotherapeutic Role of Melatonin in the Treatment of Stage IIIB and IV Non-Small Cell Lung Carcinoma

Dear Mr. Faloon:

On behalf of Cancer Treatment Centers of Americaâ, I’d like to take this opportunity to say “thank you” for your donation of the thousands of capsules of melatonin for our clinical trial investigating the effects of melatonin, given at the appropriate circadian phase, in patients with non-small cell lung cancer. Indeed, the support of the Life Extension Foundation has made this landmark study possible. I’d also like to take a moment to update you on the progress of our study.

Our participating centers have enrolled thirty-one (31) patients onto the trial since December 2002, and we are looking forward to a steady increase in the number of patients enrolled in the foreseeable future.

To implement this program, your donation of high quality 20 mg doses of melatonin saved us considerable expense and effort. As you know, both federal and local IRB regulations require that we obtain an independent assay of any chemical agent that will be used in a human clinical trial. To fulfill these requirements, randomly selected capsules of melatonin and placebos were sent for analysis (HPLC and gas chromatography) to the Roswell Park Cancer Institute (an National Cancer Institute-Designated Comprehensive Cancer Center). As expected, the Life Extension Foundation’s products achieved all specifications on purity and dose.

Your product donations are now helping us discover more about the role of melatonin in cancer treatment. Indeed, this will be the first prospective randomized cancer clinical trial in the United States to investigate: (1) whether lung cancer patients produce a nocturnal pulse of melatonin prior to therapy; (2) what fraction of patients with advanced lung cancer suffer abnormalities in their circadian activity/rest rhythm, and 3) whether or not melatonin therapy, delivered at the appropriate circadian phase, improves the quality of life and overall survival of NSC lung cancer patients.

Thank you once again for Life Extension Foundation’s continued and generous support. We look forward to keeping you updated on the progress of this landmark investigation.

Best Wishes,

Christopher G. Lis, MPH
Vice President
Research and Development
CANCER TREATMENT CENTERS OF AMERICA

References

1. Sandyk R. Possible role of pineal melatonin in the mechanisms of aging. Int J Neurosci. 1990;52:85-92.

2. Dilman VM, Anisimov VN, Ostroumova MN, Khavinson VK, Morozov VG. Increase in lifespan of rats following polypeptide pineal extract treatment. Exp Pathol Jena. 1979;17:539-545.

3. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Topics in Med Chem. 2002;2:113-132.

4. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J Pineal Res. 2003;35:12-15.

5. Cajochen C, Krauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrin. 2003;15:432-437

6. Herxheimer A, Petrie KJ. Melatonin for preventing and treating jet lag. Cochrane Database Syst Rev. 2001;1:CD001520.

7. Winczyk K, Pawlikowski M, Guerrero JM, Karasek M. Possible involvement of the nuclear rzr/ror-alpha receptor in the antitumor action of melatonin on murine colon 38 cancer. Tumour Biology. 2002;23:298-302.

8. Scott AE, Cosma GN, Frank AA, Wells RL, Gardner HS, Jr. Disruption of mitochondrial respiration by melatonin in mcf-7 cells. Toxicol & Applied Pharmacol. 2001;171:149-156.

9. Lissoni P, Barni S, Crispino S, Tancini G, Fraschini F. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Can & Clin Onc. 1989;25:789-795.

10. Neri B, de Leonardis V, Gemelli MT, et al. Melatonin as biological response modifier in cancer patients. Anticancer Res. 1998;18:1329-1332.

11. Lissoni P, Barni S, Ardizzoia A, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology. 1992;49:336-339.

12. Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology (Huntington). 1996;53:43-46.

13. Karbownik M, Reiter RJ. Antioxidative effects of melatonin in protection against cellular damage caused by ionizing radiation. Proc Soc Exp Biol Med. 2000;225:9-22.

14. Lissoni P, Brivio F, Brivio O, et al. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients. J Biol Regulators & Homeostatic Agents. 1995;9:31-33.

15. Lissoni P, Brivio O, Brivio F, et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J Pineal Res. 1996;21:239-242.

16. Inui A. Cancer anorexia-cachexia syndrome: Current issues in research and management. CA: Cancer Journal for Clinicians. 2002;52:72-91.

17. Lissoni P, Barni S, Tancini G, et al. Clinical study of melatonin in untreatable advanced cancer patients. Tumori. 1987;73:475-480.

18. Vijayalaxmi, Thomas CR Jr, Reiter RJ, Herman TS. Melatonin: From basic research to cancer treatment clinics. [review]. J Clin Oncol. 2002;20:2575-2601.

19. Barni S, Lissoni P, Paolorossi F, Crispino S, Archili C, Tancini G. A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. Tumori. 1990;76:58-60.

20. Ghielmini M, Pagani O, de Jong J, et al. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br J Cancer 1999; 80:1058-1061.

21. Lissoni P. Is there a role for melatonin in supportive care? Supportive Care in Cancer. 2002;10:110-116.

22. Lissoni P, Barni S, Ardizzoia A, Tancini G, Conti A, Maestroni G. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer. 1994;73:699-701.

23. Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: A review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev. 2003;55:325-395.

24. Kvetnoy I. Extrapineal melatonin in pathology: New perspectives for diagnosis, prognosis and treatment of illness. Neuroendocrinol Lett. 2002;23:92-96

25. Bubenik GA. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol Signals & Receptors. 2001;10:350-366.

26. Bubenik GA. Gastrointestinal melatonin: Localization, function, and clinical relevance. Digest Dis & Sci. 2002;47:2336-2348.

27. Weaver DR, Reppert SM. The mel1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport. 1996;8:109-112.

28. Ekmekcioglu C, Haslmayer P, Philipp C, et al. Expression of the mt1 melatonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res. 2001;21:85-91.

29. Woo MM, Tai CJ, Kang SK, Nathwani PS, Pang SF, Leung PC. Direct action of melatonin in human granulosa-luteal cells. J Clin Endocrinol Metab. 2001;86:4789-4797.

30. Schlabritz-Loutsevitch N, Hellner N, Middendorf R, Muller D, Olcese J. The human myometrium as a target for melatonin. J Clin Endocrinol Metab. 2003;88:908-913.

31. Klein DC. Evidence for the placental transfer of 3 h-acetyl-melatonin. Nat New Biol. 1972;237:117-118

32. Grin W, Grunberger W. A significant correlation between melatonin deficiency and endometrial cancer. Gyn & Obst Invest. 1998;45:62-65.

33. Khoory R, Stemme D. Plasma melatonin levels in patients suffering from colorectal carcinoma. J Pineal Res. 1988;5:251-258.

34. Barni S, Lissoni P, Crispino S, et al. Neuroimmunomodulation in cancer patients: Correlations between melatonin and beta-endorphin blood levels and t helper/suppressor ratio. Int J Biol Markers. 1988;3:82-86.

35. Dawson D, Gibbon S, Singh P. The hypothermic effect of melatonin on core body temperature: Is more better? J Pineal Res. 1996;20:192-197.

36. Kumar V. Melatonin: A master hormone and a candidate for universal panacea. Indian J Exp Biol. 1996;34:391-402.

37. Fowler G, Daroszewska M, Ingold KU. Melatonin does not “directly scavenge hydrogen peroxide”: Demise of another myth. Free Radic Biol Med. 2003;34:77-83.

38. Antunes F, Barclay LR, Ingold KU, et al. On the antioxidant activity of melatonin. Free Radic Biol Med. 1999;26:117-128.

39. Anisimov VN. The light-dark regimen and cancer development. Neuroendocrinology Letters. 2002;23:28-36.

40. Karbownik M, Reiter RJ. Melatonin protects against oxidative stress caused by delta-aminolevulinic acid: Implications for cancer reduction. Cancer Investigation. 2002;20:276-286.

41. Riabykh TP, Nikolaeva TG, Bodrova NB. Effects of biorhythm regulator melatonin on DNA synthesis in short-term cultures of human malignant tumors. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2000:30-33.

42. Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: Differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci. 2003;60:1407-1426

43. Lissoni P, Barni S, Cattaneo G, et al. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology. 1991;48:448-450.

44. Shiu SY, Law IC, Lau KW, Tam PC, Yip AW, Ng WT. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed mt1 receptor subtype. J Pineal Res. 2003;35:177-182.

45. Cos S, Sanchez-Barcelo EJ. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histology & Histopathology. 2000;15:637-647.

46. Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs. 2001;61:499-514.

47. Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol Lett. 2001;22:45-47.

48. Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ. Influence of melatonin on invasive and metastatic properties of mcf-7 human breast cancer cells. Cancer Research. 1998;58:4383-4390.

49. Srinivasan V. Melatonin oxidative stress and neurodegenerative diseases. Indian J Expt Biol. 2002;40:668-679.

50. Gitto E, Karbownik M, Reiter RJ, et al. Effects of melatonin treatment in septic newborns. Pediatr Res. 2001;50:756-760.

51. Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Natural Immunity. 1998;16:27-33.

52. Currier NL, Sun LZ, Miller SC. Exogenous melatonin: Quantitative enhancement in vivo of cells mediating non-specific immunity. J of Neuroimmun. 2000;104:101-108.

53. Lissoni P, Bolis S, Brivio F, Fumagalli L. A phase ii study of neuroimmunotherapy with subcutaneous low-dose il-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Antican Res. 2000;20:2103-2105.

54. Maestroni GJ. Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer. Adv Expt Med & Biol. 1999;467:217-226.

55. Lissoni P, Malugani F, Bukovec R, et al. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients. Neuroendocrinol Lett. 2003;24:83-85.

56. Raghavendra V, Agrewala JN, Kulkarni SK. Melatonin reversal of lipopolysacharides-induced thermal and behavioral hyperalgesia in mice. Eur J Pharmacol. 2000;395:15-21.

57. Shaji AV, Kulkarni SK. Central nervous system depressant activities of melatonin in rats and mice. Indian J Exp Biol. 1998;36:257-263.

58. Bruera E, Neumann CM. The uses of psychotropics in symptom management in advanced cancer. Psycho-Oncology. 1998;7:346-358.

59. Lissoni P, Rovelli F, Meregalli S, et al. Melatonin as a new possible anti-inflammatory agent. J Biol Regulators & Homeostatic Agents. 1997;11:157-159.

60. Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci. 2000;917:376-386.

61. Reiter RJ, Tan DX. Melatonin: A novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res. 2003;58:10-19.

62. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28:29-35.

63. Hill SA, Pigott KH, Saunders MI, et al. Microregional blood flow in murine and human tumours assessed using laser doppler microprobes. Br J Cancer Suppl. 1996;27:S260-263.

64. Auclerc G, Meric JB, Pommeyrol A, Rixe O, Khayat D. Anemia in cancer patients before treatment. Bull Cancer. 2003;90 Spec No:S128-132.

65. Thomas GM. Raising hemoglobin: An opportunity for increasing survival? Oncology. 2002;63 Suppl 2:19-28.

66. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002;7:492-508.

67. Lissoni P, Bucovec R, Bonfanti A, et al. Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. J Pineal Res. 2001;30:123-126.

68. Lissoni P, Cazzaniga M, Tancini G, et al. Reversal of clinical resistance to lhrh analogue in metastatic prostate cancer by the pineal hormone melatonin: Efficacy of lhrh analogue plus melatonin in patients progressing on lhrh analogue alone. Eur Urology. 1997;31:178-181.

69. Vaupel P, Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance. Int J Oncol. 2000;17:869-879.

70. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol. 1996;6:3-9.

71. Bubenik GA, Blask DE, Brown GM, et al. Prospects of the clinical utilization of melatonin. Biol Signals & Receptors. 1998;7:195-219.

72. Delagrange P, Atkinson J, Boutin JA, et al. Therapeutic perspectives for melatonin agonists and antagonists. J Neuroendocrin. 2003;15:442-448.

73. Jatoi A, Thomas CR, Jr. Esophageal cancer and the esophagus: Challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. Semin Radiat Onc. 2002;12:62-67.

74. Sorenson JR. Cu, fe, mn, and zn chelates offer a medicinal chemistry approach to overcoming radiation injury. Curr Med Chem. 2002;9:639-662.

75. Lissoni P, Tancini G, Barni S, et al. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Supportive Care in Cancer. 1997;5:126-129.

76. Cerea G, Vaghi M, Ardizzoia A, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: A randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res. 2003;23:1951-1954.

77. Granzotto M, Rapozzi V, Decorti G, Giraldi T. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal Res. 2001;31:206-213.

78. Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S. Melatonin: Reducing the toxicity and increasing the efficacy of drugs. J Pharm & Pharmacol. 2002;54:1299-1321.

79. Lissoni P, Vaghi M, Ardizzoia A, et al. A phase ii study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (p.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha. In Vivo. 2002;16:93-96.

80. Lissoni P, Barni S, Mandala M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Can. 1999;35:1688-1692.

81. Rapozzi V, Zorzet S, Comelli M, Mavelli I, Perissin L, Giraldi T. Melatonin decreases bone marrow and lymphatic toxicity of adriamycin in mice bearing tlx5 lymphoma. Life Sci. 1998;63:1701-1713.

82. Kajdaniuk D, Marek B, Kos-Kudla B. Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma melatonin and chosen hormones in breast cancer premenopausal patients. J Clin Pharm & Therap. 2001;26:297-301.

83. Jahovic N, Cevik H, Sehirli AO, Yegen BC, Sener G. Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res. 2003;34:282-287.

84. Bogdan A, Bouchareb B, Touitou Y. Ramadan fasting alters endocrine and neuroendocrine circadian patterns. Meal-time as a synchronizer in humans? Life Sci. 2001;68:1607-1615.

85. Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev. 1998;78:687-721.

86. Pevet P, Bothorel B, Slotten H, Saboureau M. The chronobiotic properties of melatonin. Cell Tissue Res. 2002;309:183-191.

87. McArthur AJ, Gillette MU, Prosser RA. Melatonin directly resets the rat suprachiasmatic circadian clock in vitro. Brain Res. 1991;565:158-161.

88. Deacon S, Arendt J. Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. Brain Res. 1995;688:77-85.

89. Fu L, Lee CC. The circadian clock: Pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3:350-361.

90. Kajdaniuk D, Marek B, Kos-Kudla B, et al. Does the negative correlation found in breast cancer patients between plasma melatonin and insulin-like growth factor-i concentrations imply the existence of an additional mechanism of oncostatic melatonin influence involved in defense?[comment]. Med Sci Monitor. 2002;8:CR457-461.

91. Callaghan BD. Does the pineal gland have a role in the psychological mechanisms involved in the progression of cancer? Medical Hypotheses. 2002;59:302-311.

92. Brzezinski A. Melatonin in humans. New Eng J Med. 1997;336:186-195.

93. Torres-Farfan C, Richter HG, Rojas-Garcia P, al. e. Mt1 melatonin receptor in the primate adrenal gland: Inhibition of adrenocorticotropin-stimulated cortisol production by melatonin. J Clin Endocrinol Metab. 2003;88:450-458.

94. Sanchez-Barcelo EJ, Cos S, Fernandez R, Mediavilla MD. Melatonin and mammary cancer: A short review. Endocr Relat Cancer. 2003;10:153-159.

95. Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: A phase ii study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer. 1995;71:854-856.

96. Lissoni P, Barni S, Tancini G, et al. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: A study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin. J Biol Regul & Homeostatic Agents. 1994;8:126-129.

97. Cos S, Verduga R, Fernandez-Viadero C, Megias M, Crespo D. Effects of melatonin on the proliferation and differentiation of human neuroblastoma cells in culture. Neurosci Lett. 1996;216:113-116.

98. Souza AV, Visconti MA, De Lauro Castrucci AM. Melatonin biological activity and binding sites in human melanoma cells. J Pineal Res. 2003;34:242-248.

99. Subramanian A, Kothari L. Suppressive effect by melatonin on different phases of 9,10-dimethyl-1,2-benzanthracene (dmba)-induced rat mammary gland carcinogenesis. Anticancer Drugs. 1991;2:297-303.

100. Rao GN, Ney E, Herbert RA. Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res & Treat. 2000;64:287-296.

101. Schernhammer ES, Laden F, Speizer FE, et al. Night-shift work and risk of colorectal cancer in the nurses’ health study. J Natl Cancer Inst. 2003;95:825-828.

102. Feychting M, Osterlund B, Ahlbom A. Reduced cancer incidence among the blind.[comment]. Epidemiology. 1998;9:490-494.

103. Travlos GS, Wilson RE, Murrell JA, Chignell CF, Boorman GA. The effect of short intermittent light exposures on the melatonin circadian rhythm and nmu-induced breast cancer in female f344/n rats. Toxicologic Pathology. 2001;29:126-136.

104. Mormont MC, Levi F. Circadian-system alterations during cancer processes: A review. Int J Cancer. 1997;70:241-247.

105. Roenneberg T, Lucas RJ. Light, endocrine systems, and cancer--a view from circadian biologists. Neuroendocrinol Lett. 2002;23 Suppl 2:82-83.

106. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study.[comment]. J Natl Cancer Inst. 2001;93:1563-1568.

107. Mazzoccoli G, Carughi S, De Cata A, et al. Neuroendocrine alterations in lung cancer patients. Neuroendocrinol Lett. 2003;24:77-82.

108. Muc-Wierzgon M, Nowakowska-Zajdel E, Zubelewicz B, et al. Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer. J Exp Clin Cancer Res. 2003;22:171-178.

109. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038-3045.

110. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994-1000

111. Lissoni P, Mandala M, Brivio F. Abrogation of the negative influence of opioids on il-2 immunotherapy of renal cell cancer by melatonin. Eur Urology. 2000;38:115-118.

112. Meares A. Regression of cancer after intensive meditation. Med J Australia. 1976;2:184.

113. Meares A. Regression of cancer of the rectum after intensive meditation. Med J Australia. 1979;2:539-540.

114. Meares A. Remission of massive metastastis from undifferentiated carcinoma of the lung associated with intensive meditation. J Am Soc Psychosomatic Dentistry & Medicine. 1980;27:40-41.

115. Massion AO, Teas J, Hebert JR, Wertheimer MD, Kabat-Zinn J. Meditation, melatonin and breast/prostate cancer: Hypothesis and preliminary data. Med Hypotheses. 1995;44:39-46.

116. Coker KH. Meditation and prostate cancer: Integrating a mind/body intervention with traditional therapies. Sem in Urol Onc. 1999;17:111-118.

117. Skene DJ, Swaab DF. Melatonin rhythmicity: Effect of age and alzheimer’s disease. Exp Gerontol. 2003;38:199-206.

118. Claustrat B, Geoffriau M, Brun J, Chazot G. Melatonin in humans: A biochemical marker of the circadian clock and an endogenous synchronizer. Neurophysiol Clin. 1995;25:351-359.

119. Bartsch C, Bartsch H, Karasek M. Melatonin in clinical oncology. Neuroendocrinology Letters. 2002;23:30-38.

120. Etzioni A, Luboshitzky R, Tiosano D, Ben-Harush M, Goldsher D, Lavie P. Melatonin replacement corrects sleep disturbances in a child with pineal tumor. Neurology. 1996;46:261-263.

121. Schulman C, Lunenfeld B. The ageing male. World J Urol. 2002;20:4-10.

122. Karasek M, Reiter RJ. Melatonin and aging. Neuroendocrinol Lett. 2002;23 Suppl 1:14-16

123. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer. 1989;64:426-433.

124. Ying SW, Niles LP, Crocker C. Human malignant melanoma cells express high-affinity receptors for melatonin: Antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharm. 1993;246:89-96.

125. Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC, Murphy E. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res. 1999;26:129-136.

126. Kobayashi Y, Itoh MT, Kondo H, et al. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J Pineal Res. 2003;35:71-74.

127. Ram PT, Yuan L, Dai J, et al. Differential responsiveness of mcf-7 human breast cancer cell line stocks to the pineal hormone, melatonin. J Pineal Res. 2000;28:210-218.

128. Marelli MM, Limonta P, Maggi R, Motta M, Moretti RM. Growth-inhibitory activity of melatonin on human androgen-independent du 145 prostate cancer cells. Prostate. 2000;45:238-244.

129. Moretti RM, Marelli MM, Maggi R, Dondi D, Motta M, Limonta P. Antiproliferative action of melatonin on human prostate cancer lncap cells. Oncology Reports. 2000;7:347-351.

130. Chuang JI, Chang TY, Liu HS. Glutathione depletion-induced apoptosis of ha-ras-transformed nih3t3 cells can be prevented by melatonin. Oncogene. 2003;22:1349-1357.

131. Guha A. Ras activation in astrocytomas and neurofibromas. Can J Neurol Sci. 1998;25:267-281.

132. Bruls E, Crasson M, Van Reeth O, Legros JJ. Melatonin. Ii. Physiological and therapeutic effects. Revue Medicale de Liege. 2000;55:862-870.

133. Cardinali DP, Brusco LI, Lloret SP, Furio AM. Melatonin in sleep disorders and jet-lag. Neuroendocrinol Lett. 2002;23:9-13.

134. Olde Rikkert MG, Rigaud AS. Melatonin in elderly patients with insomnia. A systematic review. Z Gerontol Geriatr. 2001;34:491-497.

135. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 1998;32:680-691.

136. Rohr UD, Herold J. Melatonin deficiencies in women. Maturitas. 2002;41:S85-104.

137. Fulia F, Gitto E, Cuzzocrea S, et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: Reduction by melatonin. J Pineal Res. 2001;31:343-349.

138. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003;35:125-130.

139. Reiter RJ, Tan DX, Mayo JC, Sainz RM, Lopez-Burillo S. Melatonin, longevity and health in the aged: An assessment. [review] [48 refs]. Free Rad Res. 2002;36:1323-9.

140. Pappolla MA, Chyan YJ, Poeggeler B, et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: Implications for alzheimer’s disease. J Neural Transm. 2000;107:203-231.

141. Raghavendra V, Kulkarni SK. Possible antioxidant mechanism in melatonin reversal of aging and chronic ethanol-induced amnesia in plus-maze and passive avoidance memory tasks. Free Radic Biol Med. 2001;30:595-602.

142. Brusco LI, Marquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in alzheimer’s disease. Neuroendocrinol Lett. 2000;21:39-42.

143. Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in alzheimer type dementia. J Nippon Med Sch. 2003;70:334-341.

144. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86:4727-4730.

145. Monti JM, Cardinali DP. A critical assessment of the melatonin effect on sleep in humans. Biol Signals Recept. 2000;9:328-339.

146. Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992;9:380-392.

147. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;2:CD001520.

148. Caplan LS, Schoenfeld ER, O’Leary ES, Leske MC. Breast cancer and electromagnetic fields--a review. Ann of Epidemiology. 2000;10:31-44

149. Jan JE, Tai J, Hahn G, Rothstein RR. Melatonin replacement therapy in a child with a pineal tumor. J Child Neurol. 2001;16:139-140.

150. Beskonakli E, Palaoglu S, Renda N, Kulacoglu S, Turhan T, Taskin Y. The effect of pinealectomy on immune parameters in different age groups in rats: Results of the weekly alteration of the zinc level and the effect of melatonin administration on wound healing. J Clin Neurosci. 2000;7:320-324.

151. Zeitzer JM, Ayas NT, Shea SA, Brown R, Czeisler CAICCA. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. Journal of Clinical Endocrinology & Metabolism. 2000;85:2189-2196.

152. Kneisley LW, Moskowitz MA, Lynch HG. Cervical spinal cord lesions disrupt the rhythm in human melatonin excretion. J Neural Transmission. 1978;Suppl.:311-323.

153. Volodina TV, Ol’shevskii EG, Abramov Iu V, et al. Effect of parenteral administration of melatonin on the biochemical composition of the rat granulation tissue. Vopr Med Khim. 2001;47:393-404.

154. Siegrist C, Benedetti C, Orlando A, et al. Lack of changes in serum prolactin, fsh, tsh, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res. 2001;30:34-42.

155. Gimeno MF, Landa A, Sterin-Speziale N, Cardinali DP, Gimeno AL. Melatonin blocks in vitro generation of prostaglandin by the uterus and hypothalamus. Eur J Pharmacol. 1980;62:309-317.

156. Drogovoz SM, Ryzhenko IM. The tocolytic activity of melatonin. Eksp Klin Farmakol. 1993;56:23-25

157. Cagnacci A, Arangino S, Angiolucci M, Maschio E, Melis GB. Influences of melatonin administration on the circulation of women. Am J Physiol Regul Integr Comp Physiol. 1998;274:R335-338.

158. Karasek M, Reiter RJ, Cardinali DP, Pawlikowski M. Future of melatonin as a therapeutic agent. Neuroendocrinol Lett. 2002;23:118-121.

159. Papavasiliou PS, Cotzias GC, Duby SE, Steck AJ, Bell M, Lawrence WH. Melatonin and parkinsonism. Jama. 1972;221:88-89.

160. Seabra ML, Bignotto M, Pinto LR, Jr., Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. 2000;29:193-200.

161. Luboshitzky R, Qupti G, Ishay A, Shen-Orr Z, Futerman B, Linn S. Increased 6-sulfatoxymelatonin excretion in women with polycystic ovary syndrome. Fertility & Sterility. 2001;76:506-510

162. Sutherland ER, Martin RJ, Ellison MC, Kraft M. Immunomodulatory effects of melatonin in asthma. Am J Respiratory & Critical Care Med. 2002;166:1055-1061.

163. Hardeland R, Poeggeler B. Non-vertebrate melatonin. J Pineal Res. 2003;34:233-241.

164. Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet. 1997;350:1598-1599.

165. Reiter RJ, Tan DX, Burkhardt S, Manchester LC. Melatonin in plants. Nutr Rev. 2001;59:286-290

166. Burkhardt S, Tan DX, Manchester LC, Hardeland R, Reiter RJ. Detection and quantification of the antioxidant melatonin in montmorency and balaton tart cherries (prunus cerasus). J Agric Food Chem. 2001;49:4898-4902.

167. Manchester LC, Tan DX, Reiter RJ, Park W, Monis K, Qi W. High levels of melatonin in the seeds of edible plants: Possible function in germ tissue protection. Life Sci. 2000;67:3023-3029.

168. Tan DX, Manchester LC, Hardeland R, al. e. Melatonin: A hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res. 2003;34:75-78.

169. Lissoni P, Resentini M, Mauri R, et al. Effects of tetrahydrocannabinol on melatonin secretion in man. Horm Metab Res. 1986;18:77-78.

170. Hartter S, Ursing C, Morita S, al e. Orally given melatonin may serve as a probe drug for cytochrome p450 1a2 activity in vivo: A pilot study. Clin Pharmacol Ther. 2001;70:10-16.

171. Brainard GC, Rollag MD, Hanifin JP. Photic regulation of melatonin in humans: Ocular and neural signal transduction. J Biol Rhythms. 1997;12:537-546.